HDA Opposes Gross Receipts Taxes Levied on Pharmaceutical Distributors

HDA’S POSITION

Efforts by state governments to change existing tax laws and impose a GRT on the pharmaceutical distribution industry is inherently inequitable due to the unique high value, low margin nature of the business. The application of a multi-tiered tax will make medicines less affordable, ultimately thwarting state efforts to contain healthcare costs. HDA instead supports providing alternative tax options, such as a gross margins tax or a business income tax, for distribution industries that are disproportionately affected by a tax on gross receipts.

• Distributors’ revenues are almost entirely and immediately offset by the costs of purchasing medicines, resulting in razor-thin profit margins. A gross receipts tax is not a tax on profit, but is a tax based on total sales revenue without consideration of operating costs or expenses (cost of medicine) or profit.

• A gross receipts tax has a significant financial impact on pharmaceutical distributors given the high dollar value of the products they carry. For example, even if the GRT rate is relatively low, the total tax owed becomes substantial when multiplied by the high volume and value of pharmaceutical products sold by distributors. The unique distribution business model will result in a disproportionately high tax, compared with other industries.

ISSUE

Gross receipts taxes (GRTs) are taxes on the entire sales or gross proceeds of a business and significantly impact business profits. Moreover, GRTs don’t have deductions for business costs like traditional income taxes do. They are imposed at each stage of the production chain, leading to “pyramiding,” or imposing taxes on top of other taxes. Businesses are required to pay GRTs even in years when they lose money.

Pharmaceutical distribution is an industry that suffers disproportionately from a gross receipts tax. For distribution companies operating in such a highly competitive market, it is impossible to absorb the negative financial impact of GRTs the way that other industries can. For example, at a national level, a 0.25 percent gross receipts tax would average 2.8 percent of pre-tax income for all industries. By contrast, within the healthcare distribution sector, the tax burden would be equivalent to 17.9 percent of pre-tax income — almost 6 times higher than the average industry. Applying GRTs on medicines will compound costs throughout the healthcare supply chain, likely increasing the costs of medicines for patients.

ADDITIONAL INFORMATION

The application of a GRT on medicine will have a cumulative, negative impact throughout the healthcare supply chain, as the same medicines would be taxed multiple times before reaching the patient:

• At the time of sale by the manufacturer to the distributor;
• When sold by the distributor to the pharmacy; and,
• In many states, when sold by the pharmacy to the consumer.